
A 13-year-old collaboration between Novo Nordisk and Emisphere Technologies now culminates in the acquisition of the latter by the former.
On Friday morning, Novo Nordisk announced that a final deal had been struck to take over the years-long collaborative partner, whose main asset is a technology which aids the formulation of drugs for oral ingestion – a delivery agent called Snac – which Novo Nordisk has employed in, for example, the development of semaglutide in tablet form, that is, the diabetes tablet Rybelsus.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app